Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Muacevic

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Frontiers in Oncology|February 26, 2021
Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response ModelsAnand Mahadevan, Bahman Emami, Jimm Grimm, et al.
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
The Lancet. Oncology|December 19, 2015
Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) groupIsabelle Thibault, Eric L Chang, Jason Sheehan, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2025
Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the KidneyMuhammad Ali, Rohann J M Correa, David Pryor, et al.
Neuro-Oncology|March 29, 2018
Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group reportIlya Laufer, Simon S Lo, Eric L Chang, et al.
Journal of Applied Clinical Medical Physics|April 9, 2026
Reirradiation treatment effects in the clinic (ReTEC) proposal - proof of concept based on spinal cord dose tolerance for reirradiation with stereotactic body radiotherapyJimm Grimm, Anand Mahadevan, Olusola Obayomi-Davies, et al.
World Neurosurgery|June 2, 2023
Impact of Cochlear Dose on Hearing Preservation Following Stereotactic Radiosurgery in Treatment of Vestibular Schwannomas: A Multi-Center StudySteven D Chang, Alexander Muacevic, Andrea L Klein, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Frontiers in Oncology|February 26, 2021
Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response ModelsAnand Mahadevan, Bahman Emami, Jimm Grimm, et al.
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
The Lancet. Oncology|December 19, 2015
Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) groupIsabelle Thibault, Eric L Chang, Jason Sheehan, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2025
Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the KidneyMuhammad Ali, Rohann J M Correa, David Pryor, et al.
Neuro-Oncology|March 29, 2018
Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group reportIlya Laufer, Simon S Lo, Eric L Chang, et al.
Journal of Applied Clinical Medical Physics|April 9, 2026
Reirradiation treatment effects in the clinic (ReTEC) proposal - proof of concept based on spinal cord dose tolerance for reirradiation with stereotactic body radiotherapyJimm Grimm, Anand Mahadevan, Olusola Obayomi-Davies, et al.
World Neurosurgery|June 2, 2023
Impact of Cochlear Dose on Hearing Preservation Following Stereotactic Radiosurgery in Treatment of Vestibular Schwannomas: A Multi-Center StudySteven D Chang, Alexander Muacevic, Andrea L Klein, et al.
Pageof 12